Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACH101 in Advanced or Metastatic Solid Tumors
NCT05076552Phase 1Active, not recruiting
- Sponsor
- Tachyon Therapeutics
- Start
- Feb 2023
- Primary completion
- Jul 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zavondemstat in solid tumor (advanced stage), metastatic solid tumor, gastrointestinal cancer and 1 more (2 arms), sponsored by Tachyon Therapeutics. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 1 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
zavondemstat
03
Conditions
solid tumor (advanced stage)metastatic solid tumorgastrointestinal cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05076552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076552.